Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: HTTP request failed! HTTP/1.1 403 Forbidden in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa logo

besponsa logo

Перейти к контенту

Главное меню:

besponsa logo
Welcome to BESPONSA® | BESPONSA®, Resources | BESPONSA®, EU nod for Pfizer’s Besponsa - PharmaTimes, Besponsa logo Trademark by Pfizer Inc. | trademarKing.in, besponsa-logo - Luke Fostvedt, BESPONSA™ (inotuzumab ozogamicin) | R/R B-Cell ALL , Besponsa 2017-2018 U.S. Promotional Audit Report , BESPONSA 1 mg powder for concentrate for solution for , Forms & Resources | Pfizer Oncology Together | HCP.
BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . BESPONSA is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age.. We’re committed to helping you get your prescribed BESPONSA medicine. Pfizer Oncology Together can help you understand your insurance and identify what financial support may be available for your prescribed Pfizer Oncology medicine..
Pfizer’s antibody drug conjugate Besponsa has become the first to be approved by regulators in Europe to treat some adults with the rare, aggressive cancer acute lymphoblastic leukaemia (ALL). The decision allows the drug’s use for relapsed or refractory CD22-positive ALL in patients who have. Besponsa logo by Pfizer Inc. Filed by SINGH & SINGH LALL & SETHI. The Current Status of this Trademark Brand is Registered.. Recent Academic Work. Asymptotic Results for Configuration Model Random Graphs with Arbitrary Degree Distributions (2010). Learn about the risks & benefits of BESPONSA™, an Rx treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.. The "Besponsa 2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's offering. The 5 Key Questions Addressed by this. There was a trend in favour of BESPONSA for estimated mean postbaseline scores from the EuroQoL 5 Dimension (EQ-5D) questionnaire, (BESPONSA and Investigator's choice of chemotherapy, respectively) for the EQ-5D index (0.80 versus 0.76, minimally important difference for cancer = 0.06)..
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню